These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27364775)

  • 41. Modelling and prediction of global non-communicable diseases.
    Wang Y; Wang J
    BMC Public Health; 2020 Jun; 20(1):822. PubMed ID: 32487173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commentary on a meeting entitled 'Building global capacity for non-communicable diseases (NCD) prevention: Defining direction and roles'.
    McQueen D; Pratt M; Blanchard C
    Glob Health Promot; 2013 Dec; 20(4 Suppl):93-6. PubMed ID: 24722747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noncommunicable Diseases in Low- and Middle-Income Countries: A Strategic Approach to Develop a Global Implementation Research Workforce.
    Engelgau MM; Rosenthal JP; Newsome BJ; Price L; Belis D; Mensah GA
    Glob Heart; 2018 Jun; 13(2):131-137. PubMed ID: 29970340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Putting non-communicable disease data to work in Vietnam: an investigation of community health surveillance capacity.
    Nguyen TNT; Nguyen TTT; Tran BQ; Pham CT; Perry KE; Haregu T; Oldenburg B; Kowal P
    BMC Public Health; 2023 Feb; 23(1):321. PubMed ID: 36788519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantifying research output on poverty and non-communicable disease behavioural risk factors in low-income and lower middle-income countries: a bibliometric analysis.
    Allen LN; Fox N; Ambrose A
    BMJ Open; 2017 Nov; 7(11):e014715. PubMed ID: 29133311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systems and capacity to address noncommunicable diseases in low- and middle-income countries.
    Ali MK; Rabadán-Diehl C; Flanigan J; Blanchard C; Narayan KM; Engelgau M
    Sci Transl Med; 2013 Apr; 5(181):181cm4. PubMed ID: 23596201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A narrative review of gaps in the provision of integrated care for noncommunicable diseases in India.
    Pati MK; Swaroop N; Kar A; Aggarwal P; Jayanna K; Van Damme W
    Public Health Rev; 2020; 41():8. PubMed ID: 32435518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Building leadership capacity to prevent and control noncommunicable diseases: evaluation of an international short-term training program for program managers from low- and middle-income countries.
    Erzse A; Bovet P; Paccaud F; Chestnov O; Banatvala N
    Int J Public Health; 2017 Sep; 62(7):747-753. PubMed ID: 27942746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of and training for NCD guideline implementation in LMICs: a scoping review protocol.
    Faro E; Adeagbo O; Mpinganjira MG; Chirwa T; Matanje B; Mayige M; Kavishe BB; Mmbaga B; Francis JM
    BMJ Open; 2023 Jul; 13(7):e073550. PubMed ID: 37407038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Chronology of Global Assistance Funding for NCD.
    Nugent R
    Glob Heart; 2016 Dec; 11(4):371-374. PubMed ID: 27938820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tailored support for national NCD policy and programme implementation: an over-looked priority.
    Jackson-Morris A; Nugent R
    BMJ Glob Health; 2020 Aug; 5(8):. PubMed ID: 32847822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A qualitative study of governance of evolving response to non-communicable diseases in low-and middle- income countries: current status, risks and options.
    Rani M; Nusrat S; Hawken LH
    BMC Public Health; 2012 Oct; 12():877. PubMed ID: 23067232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addressing cancer prevention and control in Armenia: tobacco control and mHealth as key strategies.
    Berg CJ; Harutyunyan A; Paichadze N; Hyder AA; Petrosyan V
    Int J Equity Health; 2021 Jan; 20(1):4. PubMed ID: 33407461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gender and leadership for health literacy to combat the epidemic rise of noncommunicable diseases.
    Manhanzva R; Marara P; Duxbury T; Bobbins AC; Pearse N; Hoel E; Mzizi T; Srinivas SC
    Health Care Women Int; 2017 Aug; 38(8):833-847. PubMed ID: 28524810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Global Burden of Disease Study and the Preventable Burden of NCD.
    Benziger CP; Roth GA; Moran AE
    Glob Heart; 2016 Dec; 11(4):393-397. PubMed ID: 27938824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addressing emerging public health threats: the Noncommunicable Disease Capacity Assessment and Planning (N-CAP) Process.
    Saad RK; Alsouri R; Kruse MH; Kufoof L; Lobanov-Rostovsky S; Richter P; Khader Y
    Front Public Health; 2024; 12():1384957. PubMed ID: 38903573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Burden of cumulative risk factors associated with non-communicable diseases among adults in Uganda: evidence from a national baseline survey.
    Wesonga R; Guwatudde D; Bahendeka SK; Mutungi G; Nabugoomu F; Muwonge J
    Int J Equity Health; 2016 Dec; 15(1):195. PubMed ID: 27905949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of non-communicable disease policies: a geopolitical analysis of 151 countries.
    Allen LN; Nicholson BD; Yeung BYT; Goiana-da-Silva F
    Lancet Glob Health; 2020 Jan; 8(1):e50-e58. PubMed ID: 31813787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-communicable Disease Surveillance in Malaysia: An Overview of Existing Systems and Priorities Going Forward.
    Chandran A; Selva Kumar S; Hairi NN; Low WY; Mustapha FI
    Front Public Health; 2021; 9():698741. PubMed ID: 34295873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Noncommunicable disease outcomes and the effects of vertical and horizontal health aid.
    Kostova D; Nugent R; Richter P
    Econ Hum Biol; 2021 May; 41():100935. PubMed ID: 33388634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.